 "Apollo Hospitals has been investing big in infrastructure and bringing in advanced technologies such as Proton Therapy for cancer treatment, which has resulted in a higher debt")
Apollo Hospitals in focus after Q1 results: Hospital chain operator Apollo Hospitals Enterprise posted a strong set of results for the first quarter of FY26 (Q1FY26), with double-digit revenue growth and robust profitability, leading most brokerages to raise their target prices and reiterate a ‘Buy’ rating on the stock – though Nomura remains cautious with a ‘Neutral’ stance.
Solid topline and profitability gains
For Q1FY26, consolidated revenue grew 15 per cent year-on-year (Y-o-Y) to ₹5,842 crore, driven by all three business segments. Healthcare Services (HCS) revenue stood at ₹2,935 crore, up 11 per cent Y-o-Y, while
